



*News Release*

## **NeurAxon, Inc. to Present at the BioCentury Future Leaders Conference March 27, 2008**

**WALTHAM, MA. March 25, 2008** – NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company's Chief Executive Officer, will present at the BioCentury Future Leaders Conference to be held Thursday, March 27, 2008 in New York City.

The NeurAxon presentation will begin at 10:30 am Eastern Time in Room 304/305 at the Millennium Broadway Hotel and Conference Center.

Dr. Bloch will provide an overview of NeurAxon and its portfolio of novel pain therapeutics, including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT agonist which is currently in Phase 2 trials for acute migraine.

### **About NeurAxon Inc.**

NeurAxon Inc. ([www.neuraxon.com](http://www.neuraxon.com)) is a leader in discovering and developing next generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.

### **Contact:**

Chris Erdman  
MacDougall Biomedical Communications  
781-235-3060, ext. 14